May 1, 2021Open Access

Toxicities and Associated Factors in Patients Receiving Temozolomide-Containing Regimens: A 12-Year Analysis of Hospital Data

Key Points

Key points are not available for this paper at this time.

Abstract

Toxicities are common among patients receiving temozolomide-containing regimens. Clinicians should be aware of factors associated with toxicities to minimize the impact of the toxicity.

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Chen et al. (Sat,) studied this question.

synapsesocial.com/papers/69d8f242ade63f05b9bedf4d https://doi.org/https://doi.org/10.2147/dddt.s305792

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse2001 · 372 citations
2Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors2009 · 87 citations
3Phase II Trial of Temozolomide (TMZ), Motexafin Gadolinium (MGd), and 60 Gy Fractionated Radiation (RT) for Newly Diagnosed Supratentorial Glioblastoma (GBM): Results of RTOG 05132011 · 2 citations
4Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy2017 · 27 citations
5EP-1204: Limited margin radiotherapy and temozolomide for glioblastoma multiforme: pattern of failure2018 · 1 citations

AI से पूछें

Bookmark

View Full Paper